Alkermes plc - Ordinary Shares (ALKS)
Frequently Asked Questions About Alkermes plc - Ordinary Shares (ALKS)
Does Alkermes have any partnerships?
Yes, Alkermes has established numerous partnerships and collaborations with other biopharmaceutical companies, academic institutions, and research organizations. These collaborations are aimed at advancing research, enhancing product development, and expanding market access for its therapies.
How does Alkermes handle research and development?
Alkermes invests heavily in research and development (R&D) to drive innovation in its product offerings. The company has a robust pipeline of therapies, utilizing cutting-edge technologies and proprietary formulations to develop new treatments and improve existing ones.
How has Alkermes performed financially?
Alkermes has demonstrated consistent financial performance, driven by sales of its marketed products and growth in its development pipeline. The company regularly reports its earnings, providing insights into revenue, expenses, and overall financial health to investors and stakeholders.
Is Alkermes plc publicly traded?
Yes, Alkermes plc is publicly traded on the NASDAQ stock exchange under the ticker symbol ALKS. The company's shares are available for purchase by investors interested in its growth in the biopharmaceutical sector.
What are some challenges Alkermes faces?
Alkermes faces several challenges typical of the biopharmaceutical industry, including regulatory hurdles, competition from other companies, and the need for successful clinical trial outcomes. Additionally, market access and pricing pressures are constant considerations for the company's strategies.
What are some recent developments or news about Alkermes?
As of the latest updates in 2023, Alkermes has been focusing on advancing its pipeline of new therapies, including ongoing clinical trials for potential treatments in CNS disorders. The company also reports on its financial performance, partnerships, and strategic collaborations in the biotech space.
What are the main products developed by Alkermes?
Alkermes has developed several key products, including ARISTADA® for the treatment of schizophrenia, VIVITROL® for alcohol dependence and opioid dependence, and other investigational therapies that target various CNS disorders and oncology indications.
What does Alkermes plc do?
Alkermes plc is a biopharmaceutical company that focuses on the development of innovative medicines for the treatment of central nervous system (CNS) disorders, as well as oncology and other diseases. The company aims to address significant unmet medical needs through advanced drug delivery systems and proprietary formulations.
What is Alkermes' approach to drug development?
Alkermes adopts a patient-centered approach to drug development, focusing on creating therapies that are not only effective but also have convenient delivery methods. This includes utilizing depot formulations and long-acting injectables to enhance adherence and improve patient outcomes.
What is ARISTADA®?
ARISTADA® is an atypical antipsychotic used for the treatment of schizophrenia. It is formulated as a long-acting injectable, allowing for less frequent dosing compared to traditional antipsychotics, helping to improve adherence to treatment regimens among patients.
What is the industry outlook for Alkermes?
The biopharmaceutical industry is expected to continue growing, influenced by advancements in science and technology, increased demand for effective treatments, and a focus on personalized medicine. Alkermes is well-positioned to capitalize on these trends with its strong pipeline and commitment to research.
What is the mission of Alkermes plc?
Alkermes' mission is to deliver innovative medicines that help patients manage life-changing diseases. The company strives to provide value to patients, healthcare providers, and stakeholders through scientifically-proven therapies and advancements in drug delivery technology.
What is the significance of Alkermes' pipeline?
Alkermes' pipeline is significant because it represents the company's commitment to innovation and addressing critical health needs. With several products in different stages of development, the pipeline offers the potential to bring new therapies to market, which can have a substantial impact on patient lives.
What is VIVITROL®?
VIVITROL® is an extended-release injectable formulation of naltrexone used to treat alcohol dependence and opioid dependence by blocking the effects of opioids and reducing cravings for alcohol. This once-monthly injection is designed to help patients maintain sobriety.
What therapeutic areas does Alkermes focus on?
Alkermes primarily focuses on central nervous system disorders, including schizophrenia and addiction, as well as oncology. The company is dedicated to developing innovative treatments that address complex medical conditions with significant patient needs.
When was Alkermes plc founded?
Alkermes plc was founded in 1987 as a private company. It later transitioned into a public company and has grown through strategic acquisitions and product development to establish itself as a leader in the biopharmaceutical industry.
Where does Alkermes conduct its clinical trials?
Alkermes conducts its clinical trials in multiple locations globally, adhering to regulatory standards and ethical guidelines. The company collaborates with various clinical sites and research organizations to recruit participants and gather clinical data.
Where is Alkermes plc located?
Alkermes plc is headquartered in Dublin, Ireland. The company also has a significant presence in the United States, with facilities in Massachusetts and other locations, enabling it to conduct research, development, and manufacturing activities.
Who are the key leaders at Alkermes?
Alkermes is led by a team of experienced executives with extensive backgrounds in biopharmaceuticals. The company's leadership includes a diverse mix of expertise in drug development, commercial strategy, and corporate governance, which drives its mission and business goals.
What is the current price of Alkermes plc - Ordinary Shares?
The current price of Alkermes plc - Ordinary Shares is 30.04
When was Alkermes plc - Ordinary Shares last traded?
The last trade of Alkermes plc - Ordinary Shares was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Alkermes plc - Ordinary Shares?
The market capitalization of Alkermes plc - Ordinary Shares is 4.99B
How many shares of Alkermes plc - Ordinary Shares are outstanding?
Alkermes plc - Ordinary Shares has 166.12M shares outstanding.